Revolution Medicines (RVMD) FCF Margin (2019 - 2023)

Revolution Medicines' FCF Margin history runs 5 years deep, the most recent figure standing at 15870.89% for Q4 2023.

• On a quarterly basis, FCF Margin fell 1547114.0% year-over-year to 15870.89% in Q4 2023; TTM through Sep 2024 was 73584.1%, a 7245026.0% decrease from a year earlier, with the FY2023 full-year figure at 3049.94%, down 240933.0% from the prior year.
• FCF Margin slipped to 15870.89% in Q4 2023 per RVMD's latest filing, from 1788.89% in the prior quarter.
• Across five years, FCF Margin topped out at 86.52% in Q4 2019 and bottomed at 15870.89% in Q4 2023.
• The 5-year median for FCF Margin is 399.75% (2022), against an average of 1459.21%.
• Across the five-year window, FCF Margin surged 176516 bps in 2022 and slumped 1547114 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 86.52% in 2019, then sank by 264 bps to 314.55% in 2020, then sank by 36 bps to 427.0% in 2021, then increased by 6 bps to 399.75% in 2022, then tumbled by 3870 bps to 15870.89% in 2023.
• Per Business Quant, the three latest RVMD FCF Margin figures stand at 15870.89% (Q4 2023), 1788.89% (Q2 2023), and 900.13% (Q1 2023).